N6-methyladenosine (m6A) in cancer therapeutic resistance: Potential mechanisms and clinical implications

Area of Science:

• Epigenetics and RNA Biology
• Cancer Research
• Pharmacology

Background:

• Cancer therapy resistance (CTR) limits treatment efficacy, leading to disease progression and metastasis.
• N6-methyladenosine (m6A) is the most prevalent internal RNA modification, regulating gene expression and cellular processes.
• m6A modifications are increasingly recognized for their role in cancer development and their potential to reverse CTR.

Purpose of the Study:

• To summarize the molecular mechanisms by which m6A modifications influence cancer therapy resistance.
• To review recent advancements in natural products and small-molecule compounds targeting m6A regulators.
• To discuss the clinical implications and therapeutic potential of targeting m6A for overcoming CTR.

Main Methods:

• Literature review of studies investigating m6A modification in cancer therapy resistance.
• Analysis of research on natural products from Traditional Chinese Medicines (TCM) and synthetic small molecules targeting m6A regulators.
• Synthesis of current understanding of m6A's role in CTR and potential therapeutic strategies.

Main Results:

• m6A modifications play a significant role in the development and progression of cancer, including the emergence of resistance.
• Specific molecular mechanisms linking m6A to CTR are being elucidated.
• Natural products and small-molecule inhibitors targeting m6A regulators show promise for overcoming CTR.

Conclusions:

• m6A modification is a critical factor in cancer therapy resistance, offering novel therapeutic targets.
• Targeting m6A regulators with natural products or small molecules, potentially in combination therapies, could improve clinical outcomes.
• Further research into m6A mechanisms and inhibitors is warranted to fully exploit their potential in combating CTR.